{"id":2232,"date":"2022-03-30T00:00:00","date_gmt":"2022-03-30T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2232"},"modified":"2022-03-30T00:00:00","modified_gmt":"2022-03-30T00:00:00","slug":"centogene-reports-fourth-quarter-and-full-year-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/","title":{"rendered":"CENTOGENE publikuje wyniki finansowe za czwarty kwarta\u0142 i ca\u0142y rok 2021"},"content":{"rendered":"<ul>\n<li>Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance<\/li>\n<li>Focus on Pharma and Diagnostics to Position for Strong Performance in 2022<\/li>\n<li>Closed $62 Million Financing Round and on Track to Exit COVID-19 Business<\/li>\n<li>Management to Host Conference Call at 2 p.m. CET\/8 a.m. ET Today<\/li>\n<\/ul>\n<p> <strong>CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 30, 2022 (GLOBE NEWSWIRE) <\/strong>\u2013 Centogene NV (Nasdaq: CNTG), sp\u00f3\u0142ka komercyjna skupiaj\u0105ca si\u0119 na generowaniu spostrze\u017ce\u0144 opartych na danych w celu diagnozowania, zrozumienia i leczenia rzadkich chor\u00f3b, og\u0142osi\u0142a dzi\u015b wyniki finansowe za czwarty kwarta\u0142 i rok obrotowy zako\u0144czony 31 grudnia 2021 r. oraz przedstawi\u0142a aktualizacj\u0119 dzia\u0142alno\u015bci.<\/p>\n<p>\u201c2021 was a transformative year, during which we further reinforced our position as the partner of choice for partners seeking innovative, new approaches to diagnose and treat rare and neurodegenerative diseases,\u201d stated Kim Stratton, Chief Executive Officer at CENTOGENE. \u201cIn the fourth quarter of 2021, we recorded solid quarter-over-quarter revenue growth in our core business diagnostics and pharma. We are well positioned and anticipate continued strengthening of our core business through 2022, as we specifically focus on biopharma to deliver on existing partnerships, while also expanding and converting our pipeline of partnership opportunities. Our commitment to maintaining our position as the partner with the most comprehensive clinically relevant data set available for research and development purposes in rare and neurodegenerative diseases remains resolute.\u201d<\/p>\n<h3>Fourth Quarter 2021 Financial Highlights<\/h3>\n<ul>\n<li>Overall revenues of \u20ac42.9 million were recorded in Q4 2021, a 39% decrease compared to \u20ac70.3 million in Q4 2020, driven primarily by the anticipated decrease of the COVID-19 testing business, partially offset by growth in the Company\u2019s Pharma and Diagnostics segments (\u201cCore Business\u201d). As expected, revenues from the COVID-19 segment decreased from \u20ac59.8 million in Q4 2020 to \u20ac28.9 million in Q4 2021 as the Company is preparing to exit this business<\/li>\n<li>Revenues from the Core Business increased by 34%, driven by revenues from the Diagnostics segment of \u20ac7.5 million in Q4 2021, an increase of 30% compared to \u20ac5.8 million in Q4 2020, and revenues from the Pharma segment of \u20ac6.5 million in Q4 2021, an increase of 39% versus \u20ac4.7 million in Q4 2020.<\/li>\n<li>Net loss of \u20ac12.3 million in Q4 2021, compared to net profit of \u20ac3.4 million in Q4 2020<\/li>\n<li>Total segment adjusted EBITDA of \u20ac11.9 million was recorded in Q4 2021 compared to \u20ac28.2 million in Q4 2020. This mainly reflects the adjusted EBITDA contribution from COVID-19 testing having decreased by \u20ac16.5 million year-over-year, partially offset by a stronger adjusted EBITDA contribution from the Pharma and Diagnostics segments<\/li>\n<\/ul>\n<h3>Full Year 2021 Financial Highlights<\/h3>\n<ul>\n<li>Overall revenues of \u20ac189.9 million were recorded in FY 2021, a 48% increase compared to \u20ac128.4 million in FY 2020. This was driven by higher revenues from the COVID-19 testing business in FY 2021 as well as year over year revenue growth in the Core Business<\/li>\n<li>Revenues from Core Business were \u20ac43.5 million in FY 2021, an increase of 11% compared to \u20ac39.1 million in FY 2020, driven mainly by Diagnostics segment growth of 26%<\/li>\n<li>Revenues from COVID-19 testing were \u20ac146.4 million in FY 2021, an increase of 64% from \u20ac89.3 million in FY 2020<\/li>\n<li>The gross profit margin was 15% in FY 2021, compared to 35% in FY 2020. The decrease was driven by the margin development in the COVID-19 testing business. This was partially offset by a 20% gross margin improvement in the Core Business<\/li>\n<li>The net loss was \u20ac46.9 million in FY 2021, compared to a net loss of \u20ac21.4 million in FY 2020<\/li>\n<li>The total segment adjusted EBITDA was \u20ac29.5 million in FY 2021 compared to \u20ac41.0 million in FY 2020 from the Company\u2019s Pharma, Diagnostics, and COVID-19 testing segments. This mainly reflected the adjusted EBITDA contribution from COVID-19 testing having decreased by \u20ac16.5 million year-over-year which was partially offset by a stronger adjusted EBITDA contribution from the Diagnostics segment<\/li>\n<li>Cash and cash equivalents were \u20ac17.8 million as of December 31, 2021, compared to \u20ac48.2 million for the period ending December 31, 2020. The reported cash position per year-end 2021 does not reflect proceeds from the debt and equity financing completed in February 2022<\/li>\n<\/ul>\n<p>\u201cWe are pleased to have exceeded the revenue guidance we forecasted for the year 2021. With the completion of the financing earlier this year, CENTOGENE is operating from a stable financial position, allowing us to deliver on our strategic initiatives, while ensuring efficiency and prudence in our operational execution,\u201d added Miguel Coego, EVP Finance &amp; Legal and Interim Chief Financial Officer of CENTOGENE.<\/p>\n<h3>Najnowsze wydarzenia biznesowe<\/h3>\n<h4>Zbiorowy<\/h4>\n<ul>\n<li>Closed $62 Million aggregate equity and debt financings to support growth plan, including \u20ac15 million (approx. $17 million) private placement from leading growth investors and a $45 million senior secured loan from Oxford Finance<\/li>\n<li>Appointed new executive and Supervisory Board leadership, including Kim Stratton as CEO and Dr. Andreas Busch as Vice Chairman of the Supervisory Board<\/li>\n<li>Added approximately 24,000 individuals to CENTOGENE\u2019s rare disease-centric Bio\/Databank in Q4 2021, bringing the total number of individuals added in FY 2021 to 94,000. This Bio\/Databank is a one-of-a-kind real-world data repository which includes samples as well as data and cell lines for rare, metabolic, and neurodegenerative diseases from patients from over 120 countries<\/li>\n<li>Authored 10 peer-reviewed scientific publications in Q4 2021, focused on generating critical insights into an array of diseases, including Parkinson\u2019s disease<\/li>\n<\/ul>\n<h4>Farmacja<\/h4>\n<ul>\n<li>Continued partnership with Pfizer under Data Access and Collaboration R&amp;D Agreement to advance the discovery and validation of novel genetic targets as candidates for the development of new therapies for rare diseases<\/li>\n<li>Enrolled first patients in an ongoing clinical study partnered with Alector, Inc. targeting data-rich genetic testing for more than 3,000 frontotemporal dementia (FTD) patients<\/li>\n<li>Expanded the clinical development partnership with Agios Pharmaceuticals to provide genomics and centralized lab support for Agios\u2019 three global, pivotal trials in thalassemia and sickle cell disease<\/li>\n<li>Joined forces with Insilico Medicine for Niemann-Pick Disease Type C (NPC) target discovery, leveraging CENTOGENE\u2019s Bio\/Databank and Artificial Intelligence (AI) to accelerate orphan drug development<\/li>\n<li>Received a digital healthcare innovation award for the Company\u2019s Artificial Intelligence (AI) platform for biomarker discovery<\/li>\n<li>Currently leading 10 observational longitudinal clinical studies to validate\/monitor biomarkers. The pilot study HPP Genetics and HAEKA project have been completed and reported to our pharma partners<\/li>\n<\/ul>\n<h4>Diagnostyka<\/h4>\n<ul>\n<li>Released CentoCloud, a cloud-based, global bioinformatics solution enabling decentralized analysis, interpretation, and quality reporting for laboratories around the world<\/li>\n<li>Signed a collaboration with TWIST Bioscience on the development and commercialization of custom assay kits for rare diseases<\/li>\n<li>Reported order intake of 15,300 test requests in Q4 2021, which represents a 30% increase compared to 11,750 in the same period in 2020.<\/li>\n<\/ul>\n<h3>Testowanie na COVID-19<\/h3>\n<ul>\n<li>Processed 456,100 test requests for SARS-CoV-2 testing in Q4 2021<\/li>\n<li>Initiated the phase out of the COVID-19 testing services by the end of Q1 2022.<\/li>\n<\/ul>\n<h3>Prognozy finansowe na rok 2022<\/h3>\n<p>The Company has issued 2022 annual guidance and expects total revenues to be in the range of \u20ac68 million to \u20ac70 million. The portion of total revenues derived from COVID-19 testing is expected to be approximately \u20ac18 million with expected phaseout at the end of Q1 2022. The Company expects year-over-year growth in Core Business revenues (i.e., revenues derived from the Pharma and Diagnostics segments) to be between 15% to 20%.<\/p>\n<h3>Conference Call Information<\/h3>\n<p>Management will host a conference call at 2 p.m. CET\/8 a.m. ET on March 30, 2022, to discuss financial results and recent developments. To access the conference call and webcast, please register at: <a href=\"http:\/\/emea.directeventreg.com\/registration\/5737758 \" title=\"Conference Call Information Register\">http:\/\/emea.directeventreg.com\/registration\/5737758 <\/a><\/p>\n<p>Po rejestracji ka\u017cdy uczestnik otrzyma dane do po\u0142\u0105czenia telefonicznego, kod dost\u0119pu do wydarzenia bezpo\u015bredniego oraz unikalny identyfikator rejestruj\u0105cego. Rejestruj\u0105cy mog\u0105 do\u0142\u0105czy\u0107 do po\u0142\u0105czenia do 10 minut przed jego rozpocz\u0119ciem.<\/p>\n<p>The webcast of the conference call will also be available on the Investor Relations page of the Company\u2019s website at <a href=\"http:\/\/investors.centogene.com\" title=\"Relacje inwestorskie\">http:\/\/investors.centogene.com<\/a>.<\/p>\n<h3>O firmie CENTOGENE<\/h3>\n<p>CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne, genetyczne i multiomiczne w celu diagnozowania, zrozumienia i leczenia chor\u00f3b rzadkich. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych poprzez wykorzystanie naszej rozleg\u0142ej wiedzy i danych na temat chor\u00f3b rzadkich. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 bada\u0144 nad chorobami rzadkimi, opart\u0105 na naszym repozytorium danych dotycz\u0105cych ponad 600 000 pacjent\u00f3w z ponad 120 kraj\u00f3w.<\/p>\n<p>Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi pacjent\u00f3w i kultur kom\u00f3rkowych. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma skoncentrowana na kompleksowej analizie danych wielopoziomowych w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych. Umo\u017cliwia ona lepsz\u0105 identyfikacj\u0119 i stratyfikacj\u0119 pacjent\u00f3w oraz ich chor\u00f3b podstawowych, co umo\u017cliwia i przyspiesza odkrywanie, rozw\u00f3j i dost\u0119p do lek\u00f3w sierocych. Na dzie\u0144 31 grudnia 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z ponad 30 partnerami farmaceutycznymi.<\/p>\n<p>Obserwuj nas na <a href=\"https:\/\/de.linkedin.com\/company\/centogene\" target=\"_blank\" title=\"Link do LinkedIn\">LinkedIn<\/a><\/p>\n<h3>O\u015bwiadczenia prognostyczne<\/h3>\n<p>Niniejsza informacja prasowa zawiera \u201co\u015bwiadczenia prognostyczne\u201d w rozumieniu federalnych przepis\u00f3w dotycz\u0105cych papier\u00f3w warto\u015bciowych w Stanach Zjednoczonych. Zawarte w niej o\u015bwiadczenia, kt\u00f3re nie maj\u0105 jednoznacznie historycznego charakteru, maj\u0105 charakter prognostyczny, a s\u0142owa \u201cprzewidywa\u0107\u201d, \u201cwierzy\u0107\u201d, \u201ckontynuowa\u0107\u201d, \u201coczekiwa\u0107\u201d, \u201cszacowa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cprognozowa\u0107\u201d oraz podobne wyra\u017cenia i czasowniki w czasie przysz\u0142ym lub warunkowym, takie jak \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cpowinien\u201d, \u201cm\u00f3g\u0142by\u201d, \u201cmo\u017ce\u201d, \u201cmo\u017ce\u201d i \u201cmo\u017ce\u201d, maj\u0105 na celu identyfikacj\u0119 o\u015bwiadcze\u0144 prognostycznych. Takie o\u015bwiadczenia prognostyczne wi\u0105\u017c\u0105 si\u0119 ze znanymi i nieznanymi ryzykami, niepewno\u015bciami i innymi istotnymi czynnikami, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki, efektywno\u015b\u0107 lub osi\u0105gni\u0119cia CENTOGENE b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od jakichkolwiek przysz\u0142ych wynik\u00f3w, efektywno\u015bci lub osi\u0105gni\u0119\u0107 wyra\u017conych lub dorozumianych w o\u015bwiadczeniach prognostycznych. Takie ryzyka i niepewno\u015bci obejmuj\u0105 mi\u0119dzy innymi negatywne warunki gospodarcze na ca\u0142ym \u015bwiecie oraz ci\u0105g\u0142\u0105 niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, wp\u0142yw pandemii COVID-19 na nasz\u0105 dzia\u0142alno\u015b\u0107 i wyniki operacyjne, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i politykach rz\u0105dowych, presj\u0119 wynikaj\u0105c\u0105 ze wzrostu konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zan\u0105 z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w, nasze uzale\u017cnienie od stron trzecich i partner\u00f3w, w tym nasz\u0105 zdolno\u015b\u0107 do zarz\u0105dzania wzrostem i nawi\u0105zywania nowych relacji z klientami, nasz\u0105 zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasz\u0105 zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasz\u0105 zale\u017cno\u015b\u0107 od kluczowego personelu, nasz\u0105 zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych, nasz\u0105 zdolno\u015b\u0107 do usprawnienia wykorzystania got\u00f3wki, nasze zapotrzebowanie na dodatkowe finansowanie i nasz\u0105 zdolno\u015b\u0107 do kontynuowania dzia\u0142alno\u015bci lub inne czynniki. Aby uzyska\u0107 wi\u0119cej informacji na temat ryzyka i niepewno\u015bci, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki b\u0119d\u0105 si\u0119 r\u00f3\u017cni\u0107 od tych wyra\u017conych w niniejszych o\u015bwiadczeniach prognostycznych, a tak\u017ce ryzyka zwi\u0105zanego z dzia\u0142alno\u015bci\u0105 CENTOGENE og\u00f3lnie, zapoznaj si\u0119 z czynnikami ryzyka CENTOGENE przedstawionymi w formularzu 20-F z\u0142o\u017conym przez CENTOGENE 15 kwietnia 2021 r. w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) oraz w p\u00f3\u017aniejszych dokumentach z\u0142o\u017conych w SEC. Wszelkie o\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym obowi\u0105zuj\u0105 wy\u0142\u0105cznie na dzie\u0144 jego sporz\u0105dzenia, a CENTOGENE wyra\u017anie zrzeka si\u0119 obowi\u0105zku aktualizacji jakichkolwiek o\u015bwiadcze\u0144 prognostycznych, niezale\u017cnie od tego, czy wynika to z nowych informacji, przysz\u0142ych zdarze\u0144, czy z innych przyczyn.<\/p>\n<h5>Kontakt dla medi\u00f3w: &nbsp;<\/h5>\n<p>CENTOGENE<br \/> Ben Legg<br \/> Komunikacja korporacyjna&nbsp;<br \/> <a href=\"mailto:press@centogene.com\" title=\"Napisz e-mail\">press(at)centogene(dot)com<\/a><\/p>\n<p>Lennart Streibel<br \/> Relacje inwestorskie<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Napisz e-mail\">investor.relations(at)centogene(dot)com&nbsp;<\/a><\/p>\n<p>Stern IR &nbsp;<br \/> Brendan Payne<br \/> +1 (212) 698 8695<br \/> <a href=\"mailto:brendan.payne@sternir.com\" title=\"Napisz e-mail\">brendan.payne(at)sternir(dot)com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Massachusetts i ROSTOCK, Niemcy oraz BERLIN, 30 marca 2022 r. (GLOBE NEWSWIRE) \u2013 Centogene NV (Nasdaq: CNTG), sp\u00f3\u0142ka komercyjna skupiaj\u0105ca si\u0119 na generowaniu spostrze\u017ce\u0144 opartych na danych w celu diagnozowania, zrozumienia i leczenia rzadkich chor\u00f3b, og\u0142osi\u0142a dzi\u015b wyniki finansowe za czwarty kwarta\u0142 i rok obrotowy zako\u0144czony 31 grudnia 2021 r. oraz przedstawi\u0142a aktualizacj\u0119 dzia\u0142alno\u015bci.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2232","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 30, 2022 (GLOBE NEWSWIRE) \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-30T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results\",\"datePublished\":\"2022-03-30T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/\"},\"wordCount\":1765,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/\",\"name\":\"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2022-03-30T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 30, 2022 (GLOBE NEWSWIRE) \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update.","og_url":"https:\/\/www.centogene.com\/pl\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/","og_site_name":"CENTOGENE","article_published_time":"2022-03-30T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"9 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results","datePublished":"2022-03-30T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/"},"wordCount":1765,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/","url":"https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/","name":"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2022-03-30T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-reports-fourth-quarter-and-full-year-2021-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2232"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2232\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}